Hyperhidrosis Treatment — Botulinum Toxin

Hyperhidrosis treatment at Laserstudio uses botulinum toxin (Dysport) injections to temporarily block the sympathetic nerve signals that trigger excessive sweating in the underarms, palms, or soles — producing a 6–12 month reduction in sweat secretion from a single session lasting under 15 minutes. MUDr. Bednář administers multiple microinjections across the treatment area, each targeting a sweat gland cluster. The procedure is minimally painful; EMLA topical anaesthetic cream is available for patients who prefer additional comfort. Onset occurs within 2 weeks, and results typically extend with each successive treatment as the sweat glands undergo progressive atrophy. The treatment is appropriate for both primary focal hyperhidrosis (a neurological condition) and secondary hyperhidrosis in other body regions.

Hyperhidrosis — excessive, uncontrollable sweating disproportionate to thermoregulatory need — affects approximately 3% of the population and is most commonly focal in distribution, affecting the axillae (underarms), palms, soles, or craniofacial region. At Laserstudio, the treatment of choice is intradermal botulinum toxin injection, which provides predictable and sustained anhidrosis (sweat suppression) for 6–12 months from a single session. The mechanism relies on botulinum toxin type A's inhibitory effect on the acetylcholine release at the neuroglandular junction. Sweat glands are innervated by cholinergic sympathetic nerve fibres; by blocking acetylcholine release at these junctions, botulinum toxin prevents the glands from receiving the signal to secrete, producing complete local anhidrosis within the injected area. Unlike its use in wrinkle treatment, the toxin is injected intradermally (very superficially) rather than into muscle, targeting the eccrine sweat gland networks. MUDr. Bednář performs the procedure using Dysport — a botulinum toxin type A preparation with an established safety record in hyperhidrosis indications. The session takes under 15 minutes: the axillary skin is mapped into a grid of injection points spaced 1–2 cm apart, and 2–5 units of Dysport are delivered per point with a fine-gauge needle. The total session involves approximately 20–40 injection points per axilla. A Minor's starch-iodine test can be performed before injection to precisely map the active sweat zones, though the clinic typically treats the full axillary vault by standard protocol. EMLA topical anaesthetic cream is available for patients who find the injection sensation uncomfortable, applied 30–45 minutes before the session. Effects begin within 3–7 days and reach maximum suppression by 2 weeks. Duration of anhidrosis is 6–12 months in most patients; with each successive treatment, the duration tends to extend as the sweat glands undergo progressive denervation atrophy. The treatment is indicated for primary focal axillary hyperhidrosis and is also used off-label for palmar (palms), plantar (soles), and craniofacial hyperhidrosis — pricing for these areas is determined at consultation.